GB202117005D0 - New pharmaceutical composition - Google Patents

New pharmaceutical composition

Info

Publication number
GB202117005D0
GB202117005D0 GBGB2117005.5A GB202117005A GB202117005D0 GB 202117005 D0 GB202117005 D0 GB 202117005D0 GB 202117005 A GB202117005 A GB 202117005A GB 202117005 D0 GB202117005 D0 GB 202117005D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
new pharmaceutical
new
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2117005.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexo AB
Original Assignee
Orexo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo AB filed Critical Orexo AB
Priority to GBGB2117005.5A priority Critical patent/GB202117005D0/en
Publication of GB202117005D0 publication Critical patent/GB202117005D0/en
Priority to ARP220103247A priority patent/AR127783A1/en
Priority to PCT/GB2022/052985 priority patent/WO2023094818A1/en
Priority to TW111145223A priority patent/TW202329916A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
GBGB2117005.5A 2021-11-25 2021-11-25 New pharmaceutical composition Ceased GB202117005D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2117005.5A GB202117005D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition
ARP220103247A AR127783A1 (en) 2021-11-25 2022-11-25 PHARMACEUTICAL COMPOSITION COMPRISING BIOPHARMACEUTICAL DRUGS COMPOUNDS
PCT/GB2022/052985 WO2023094818A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising biopharmaceutical drug compounds
TW111145223A TW202329916A (en) 2021-11-25 2022-11-25 New pharmaceutical composition comprising biopharmaceutical drug compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2117005.5A GB202117005D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB202117005D0 true GB202117005D0 (en) 2022-01-12

Family

ID=79601488

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2117005.5A Ceased GB202117005D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition

Country Status (1)

Country Link
GB (1) GB202117005D0 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702362A (en) 1995-05-26 1997-12-30 Bayer Aktiengesellschaft Nasal applicator
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
US20050001411A1 (en) 2001-09-06 2005-01-06 Christian Theiss Method for the determination of parameters of a seat passenger
US6938798B2 (en) 2000-12-08 2005-09-06 Tebro S.A. Fluid or powdery product dispensing device
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
WO2010142696A1 (en) 2009-06-11 2010-12-16 Charité - Universitätsmedizin Berlin Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US20110045088A1 (en) 2009-07-31 2011-02-24 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
US9724713B2 (en) 2013-07-05 2017-08-08 Aptar France Sas Fluid or powdery product dispensing device
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. Dry powder compositions for intranasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702362A (en) 1995-05-26 1997-12-30 Bayer Aktiengesellschaft Nasal applicator
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
US6938798B2 (en) 2000-12-08 2005-09-06 Tebro S.A. Fluid or powdery product dispensing device
US20050001411A1 (en) 2001-09-06 2005-01-06 Christian Theiss Method for the determination of parameters of a seat passenger
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
WO2010142696A1 (en) 2009-06-11 2010-12-16 Charité - Universitätsmedizin Berlin Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US20110045088A1 (en) 2009-07-31 2011-02-24 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
US9724713B2 (en) 2013-07-05 2017-08-08 Aptar France Sas Fluid or powdery product dispensing device
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. Dry powder compositions for intranasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Aulton's Pharmaceutics: The Design and Manufacture of Medicines", 2017, ELSEVIER
"Pharmaceutical Dosage Forms: Tablets", vol. 1, 2008, CRC PRESS
"Remington: The Science and Practice of Pharmacy", 2020, PHARMACEUTICAL PRESS
"The HLB System: A Time-Saving Guide to Emulsifier Selection", 1976, ICI AMERICAS INC, pages: 20 - 21
BERTAN ET AL., EUR. J. PHARM. SCI., vol. 27, 2006, pages 62
GANDHI, ADVANCED DRUG DELIVERY REVIEWS, vol. 43, 1994, pages 67
J. DRUG DELIVERY, 2018, pages 1 - 19
LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 2015, CBS
MOHANACHANDRAN ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, vol. 6, 2011, pages 105
ROWE ET AL.: "Handbook of Pharmaceutical Excipients", 2009
SHOJAEI, J. PHARM. PHARMACEUTICAL SCI., vol. 15, 1998, pages 19

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
IL304290A (en) Pharmaceutical composition
GB201911517D0 (en) Pharmaceutical composition
FI3908321T3 (en) Pharmaceutical composition
GB202117005D0 (en) New pharmaceutical composition
GB202117007D0 (en) New pharmaceutical composition
GB202117015D0 (en) New pharmaceutical composition
GB202018901D0 (en) New pharmaceutical composition
GB202009905D0 (en) New pharmaceutical composition
GB202007306D0 (en) New pharmaceutical composition
GB202007328D0 (en) New pharmaceutical composition
GB202208464D0 (en) Pharmaceutical composition
GB202109271D0 (en) Pharmaceutical composition
GB202108387D0 (en) Pharmaceutical composition
GB202107518D0 (en) Pharmaceutical composition
GB202105858D0 (en) Pharmaceutical composition
GB202105462D0 (en) Pharmaceutical composition
GB202105049D0 (en) Pharmaceutical composition
GB202105047D0 (en) Pharmaceutical composition
GB202104224D0 (en) Pharmaceutical composition
GB202102095D0 (en) Pharmaceutical composition
GB202102100D0 (en) Pharmaceutical composition
GB202101634D0 (en) Pharmaceutical composition
GB202101640D0 (en) Pharmaceutical composition
GB202101638D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)